NOSA announces that MDR certificates have been issued for Nozoil
Nosa Plugs AB (publ) (“NOSA” or the “Company”) announces that MDR certificates have been issued for Nozoil® Nasal Spray Original and Nozoil® Nasal Spray Menthol. The products are Class IIa medical devices. The certificates were issued on 5 November 2026 by Intertek Medical Notified Body AB.
The Company now owns the technical documentation for the products. The certification and ownership of the documentation mark an important step in the work on Nozoil that NOSA has previously described.
The technical documentation contains evidence supporting the products’ safety and performance. Ownership gives NOSA greater control over future product development and market launches. It also puts NOSA in a stronger position to realise synergies from the acquisition of Pharmacure.
Following a long and protracted certification process, work to improve the product’s gross margin and launch it in new markets can now resume.
“This is an important milestone for NOSA and for the continued development of Nozoil. The delay in obtaining the technical documentation has affected the timing of several initiatives we had planned for the year. Now that the certificates have been issued and the Company owns the technical documentation, we can continue working on product development and the long-term synergies from the acquisition of Pharmacure,” says Adrian Liljefors, CEO of Nosa Plugs AB.